AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Pros and Cons of a Single Asset Approach to Development
Cameron: We have been addicted to platforms for the last, let's say at least five years during this kind of last cycle. And there are some companies that really need to be a platform and give the justification for investing hundreds of millions of dollars pre-clinically on a single IP platform like Moderna or CRISPR. So my fascination is how do you create a company around those single hypothesis assets that represent the majority or at least the plurality of all drugs to be developed? He says Cambrian has an asset centric model where it starts early with pharma partnering conversations and looks for a liquidity event later in life. Cameron: If you want to be enduring R&